Gundegmaa Uudamsaikhan, Raadan Odbileg, Wu Hsing-Chieh, Wang Hsian-Yu, Wu Min-Chia, Chu Chun-Yen
International Degree Program in Animal Vaccine Technology, International College, Pingtung Taiwan.
Graduate Institute of Animal Vaccine Technology, College of Veterinary Medicine, National Pingtung University of Science and Technology, Neipu, Pingtung 91201, Taiwan.
J Vet Res. 2023 Mar 17;67(1):23-31. doi: 10.2478/jvetres-2023-0014. eCollection 2023 Mar.
Bovine adenovirus (BAdV) type 3 causes respiratory and gastroenteric diseases of varying severity in cattle, particularly newborn calves. Trials have been conducted of a vaccination against the diseases caused by BAdV using both modified live-virus and inactivated-virus preparations in cattle, but no commercial BAdV-3 vaccine has yet reached the market. Therefore, there is an urgent need to develop new, safe, and effective vaccines against BAdV-3.
Recombinant hexon protein (rhexon) of BAdV-3 was expressed in the system to evaluate immune response in mice and goats. Antibody responses and cytokine levels were analysed and the effects of administrations of different amounts of recombinant protein compared. Long-term antibody production was evaluated by indirect ELISA, and the total immunoglobulin G secreted by goats and mice immunised with the purified rhexon protein was determined.
The immunised mice had a stronger antibody response than the control group at eight weeks post vaccination. The immunised groups also showed significantly higher (P ˂ 0.05) expression of interferon-γ, interleukin 2 (in mice), and interleukin 21 (in goats) at four weeks. Furthermore, vaccination with rhexon was able to induce long-term antibody production for at least 16 weeks in mice and goats.
The rhexon protein induced immune responses, especially long-term antibody production and T helper 1 cell cytokine production in mice and goats. The immunogenic properties of this protein make it a promising subunit vaccine antigen.
3型牛腺病毒（BAdV）可引发牛，尤其是新生犊牛不同严重程度的呼吸道和胃肠道疾病。已开展了使用减毒活病毒和灭活病毒制剂对牛进行针对BAdV所致疾病的疫苗接种试验，但尚无商业化的BAdV - 3疫苗上市。因此，迫切需要研发新型、安全且有效的抗BAdV - 3疫苗。
在[具体系统名称]中表达BAdV - 3的重组六邻体蛋白（rhexon），以评估其在小鼠和山羊中的免疫反应。分析抗体反应和细胞因子水平，并比较不同剂量重组蛋白给药的效果。通过间接ELISA评估长期抗体产生情况，并测定用纯化的rhexon蛋白免疫的山羊和小鼠分泌的总免疫球蛋白G。
接种疫苗的小鼠在接种后8周时的抗体反应比对照组更强。免疫组在4周时还显示出干扰素 - γ、白细胞介素2（在小鼠中）和白细胞介素21（在山羊中）的表达显著更高（P ˂ 0.05）。此外，用rhexon疫苗接种能够在小鼠和山羊中诱导至少16周的长期抗体产生。
rhexon蛋白诱导了免疫反应，尤其是在小鼠和山羊中诱导了长期抗体产生以及辅助性T1细胞细胞因子产生。该蛋白的免疫原性使其成为一种有前景的亚单位疫苗抗原。
